However, we detected no change in the expression of Bim or Bad proteins in DT-061–treated CLL cells (data not shown), potentially because of differences in cell type and/or the PP2A activation mechanism used in our study. Here, BCL2L11 is linked to B-cell chronic lymphocytic leukemia.